Latest:
Building Upon Scaffolds
Cancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Authors
Glenn J. Hanna, MD
Glenn J. Hanna, MD, is the director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program) and director of the Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School
Latest:
Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer
Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.
Megan Melody, MD
Megan Melody, MD, is a hematologist/oncologist at Tampa General Hospital (TGH) and TGH Cancer Center.
Latest:
Dr Melody on the Influence of Female Mentorship on Her Research Career in Hematologic Oncology
Megan Melody, MD, discusses the importance of female mentorship on her career development as a hematologist/oncologist.
Timothy Schmidt, MD, University of Wisconsin
Latest:
Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma
Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
Sohail Dhanji, MD
Latest:
Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer
Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.
Jordyn Silverstein, MD
Jordyn Silverstein, MD, is a hematology/oncology fellow at UCLA Health.
Latest:
Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer
Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.
Kai Conrad Cecil Johnson, MD
Latest:
Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast Cancer
Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.
Ajay Chari, MD
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Lynn G. Feun, MD
Latest:
Dr Feun on the Evolving Treatment Paradigm in HCC
Lynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.
Justin Moser, MD
Justin Moser, MD, is a medical oncologist at HonorHealth and an associate clinical investigator at HonorHealth Research Institute.
Latest:
Dr Moser on Treatment Considerations After Progression on Frontline PD-1 Inhibitors in Melanoma
Justin Moser, MD, discusses key considerations for second-line treatment selection for patients with melanoma who have progressed on PD-1 inhibitors.